Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Resverlogix Corp. (T:RVX)

Business Focus: Bio Therapeutic Drugs

Jan 18, 2022 07:15 am ET
Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment
Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today that enrollment and dosing of patients has commenced in a Phase 2b study at a site at the University of Alberta Hospital in Edmonton. The trial will evaluate the safety and...
Dec 16, 2021 03:00 pm ET
Resverlogix: The Future of Drug Development, CEO Clip Video
Vancouver, British Columbia--(Newsfile Corp. - December 16, 2021) - Resverlogix Corp. (TSX: RVX) - Donald McCaffrey, President & CEO speaks about the late-stage biotechnology company and their flagship drug - Apabetalone.
Dec 13, 2021 06:00 am ET
Resverlogix Announces Corporate Update Webcast and Conference Call
Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced that they will be hosting a corporate update webcast and conference call on Thursday, December 16th, 2021 at 2:00 pm MST. Webcast link:...
Nov 15, 2021 09:55 am ET
Zenith and Newsoara Biopharma Announce Expanded Licensing and Investment
Zenith Capital Corp. (“Zenith” or the “Company”) announced today that Zenith Epigenetics Ltd. (“Zenith Epigenetics”), a wholly-owned subsidiary of Zenith Capital, has entered into a licensing agreement with Newsoara Biopharma Co., Ltd. (“Newsoara”)...
Nov 03, 2021 08:00 am ET
Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-African Economy to Support the Development of Apabetalone for COVID-19 Patients
Resverlogix Corp. (“Resverlogix” or the Company”) (TSX: RVX), a world leader in epigenetics or gene regulation, is pleased to announce today that it has entered into a cooperation agreement with the Supreme Council of the Arab-African Economy which...
Nov 01, 2021 08:30 am ET
Resverlogix In Active Discussions With The Kingdom of Morocco’s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Drug Apabetalone
Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX), a world leader in epigenetics or gene regulation, is pleased to announce today that it is in active discussions with the Kingdom of Morocco’s Ministry of Health for possible Phase 2...
Oct 29, 2021 08:30 am ET
Resverlogix to Participate in Leading Scientific Conferences
Resverlogix Corp. (“Resverlogix” or the Company”) (TSX: RVX), a world leader in epigenetics or gene regulation, today announces its virtual participation at the following scientific conferences: American Society of Nephrology – Kidney Week 2021...
Oct 13, 2021 08:00 am ET
Resverlogix to Present at Upcoming Conferences
Resverlogix Corp. (“Resverlogix” or the Company”) (TSX: RVX), a world leader in epigenetics or gene regulation, announces today that President and CEO Donald McCaffrey will be presenting virtually at the following conferences: 14th Annual LD Micro...
Oct 12, 2021 04:35 pm ET
Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX), today announces the approval of its COVID-19 clinical trial of apabetalone by the Health Research Ethics Board (HREB) – Biomedical Panel at the University of Alberta. This approval...
Sep 13, 2021 08:00 am ET
Study Demonstrates Resverlogix’s Apabetalone Treatment Significantly Improves Cognition and Reduces Cognitive Decline Among Patients with Both Cardiovascular Disease and Diabetes Mellitus
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX), a world leader in epigenetics, or gene regulation, announces today new data that demonstrates their first-in-class oral small molecule BET inhibitor candidate Apabetalone significantly...
Sep 08, 2021 08:00 am ET
Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX), a world leader in epigenetics, or gene regulation, today announces that its investigational epigenetic therapeutic apabetalone met the primary endpoint in an investigator led pulmonary...
Jul 06, 2021 06:00 am ET
Resverlogix Announces Management Change
Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced that Ken Lebioda is stepping down as Senior Vice President, Business and Corporate Development, effective immediately. “We would like to thank Ken for his important contributions over many...
Jun 24, 2021 08:00 am ET
Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in Metastatic Castration-Resistant Prostate Cancer
Zenith Capital Corp. (“Zenith” or the “Company”), a clinical stage pharmaceutical company focused on the development of novel epigenetic combination therapies for the treatment of cancers, announces the publication of an important study which has...
Jun 23, 2021 12:16 am ET
Resverlogix Announces Voting Results from the 2021 Meeting of Shareholders
Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual and Special Meeting of Shareholders (the “Meeting”) in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected six (6) Board...
Jun 03, 2021 08:04 am ET
Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone for COVID-19 in the United States and Canada
Resverlogix Corp. ("Resverlogix") (TSX:RVX) and EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, today announced a partnership to support planned commercialization of apabetalone in the United...
May 21, 2021 05:10 pm ET
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Acquires Additional Securities of Resverlogix Corp.
Calgary, Alberta--(Newsfile Corp. - May 21, 2021) - Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") announces that on May 13, 2021, it acquired 10% secured convertible debentures due May 13, 2022, of Resverlogix Corp. (TSX: RVX) (OTC Pink: RVXCF) (the "Company") in the principal amount of US$6 million and 300,000 common share purchase warrants of the Company by way of a private placement (the "Private Placement") for a purchase price of US$6 million (Cdn$7.4 million).
May 05, 2021 10:01 am ET
Resverlogix Announces US$6 Million Debenture Financing
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that it has entered into an investment agreement with a subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (“Hepalink”) which provides for Hepalink to...
Apr 27, 2021 01:41 pm ET
Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “Effect of Apabetalone on Major Adverse Cardiovascular Events in Patients with Chronic Kidney Disease, Type-2 Diabetes...
Apr 22, 2021 08:00 am ET
Zenith Epigenetics Announces Clinical Collaboration with Astellas
Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a clinical stage biotechnology company focused on the development of novel epigenetic combination therapies for the treatment of cancers, announces it has entered into an agreement with Astellas...
Apr 20, 2021 08:00 am ET
Apabetalone’s Positive Impact on COVID-19 in Human Lung Cells Published in Biomedicines
Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today the publishing of an article titled: “Bromodomain and extraterminal protein inhibitor, apabetalone (RVX-208), reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro”, in...
Apr 12, 2021 08:00 am ET
Health Canada Issues Resverlogix Authorization to Begin Immediate Clinical Studies of Apabetalone for COVID-19
Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that it has successfully received its desired “No Objection Letter” from Health Canada. It has approved the COVID-19 Clinical Trial Application for apabetalone. The planned Phase 2...
Mar 17, 2021 08:00 am ET
Apabetalone’s Beneficial Effects on COVID-19 Published in Prestigious Scientific Journal Cell
Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today the publishing of an article, titled: “BET Inhibition Blocks Inflammation-Induced Cardiac Dysfunction and SARS-CoV-2 Infection”, in Cell, a high-impact scientific journal. This comes...
Mar 15, 2021 10:34 am ET
Apabetalone Treatment Prevents COVID-19 Infection of Human Lung Cells
Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today the publishing of a new article titled: “Bromodomain and extraterminal protein inhibitor, apabetalone (RVX-208), reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro”, on...
Mar 15, 2021 08:00 am ET
Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the dosing of first patient with a triple combination of ZEN-3694 + Merck’s immune check point inhibitor, KEYTRUDA, + Pfizer’s androgen receptor signaling inhibitor (ARSI), XTANDI,...
Mar 12, 2021 04:30 pm ET
Resverlogix Announces Change in Fiscal Year-End to December 31
Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) today announces that it is changing its fiscal year-end to December 31, from its current fiscal year-end of April 30. The notice for the year-end change required under National Instrument...
Mar 03, 2021 08:00 am ET
New Published Evidence of Apabetalone’s Beneficial Effects on COVID-19
Resverlogix Corp. ("Resverlogix") (TSX:RVX) and QIMR Berghofer Medical Research Institute (“QIMR Berghofer”), one of Australia’s most successful medical research institutes, announced today the publishing of a new article providing evidence of...
Jan 27, 2021 05:35 pm ET
Resverlogix Reschedules Update Webcast and Conference Call
Resverlogix Corp. (“Resverlogix”, or the "Company") (TSX:RVX) announces that it has postponed the webcast and conference call, previously scheduled for January 28th, 2021, by one week to February 4th, 2021 at 10:00 am MT. This will allow the...
Jan 18, 2021 07:30 am ET
Resverlogix Announces Update Webcast and Conference Call
Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today announced that on January 28th, 2021 at 10:00 am MT, it will be hosting a webcast and conference call for the purpose of updating stakeholders regarding three key areas:...
Jan 12, 2021 08:00 am ET
Apabetalone’s Positive Effect on Hospitalized Patients Involving Heart Failure
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis...
Dec 22, 2020 05:17 pm ET
Resverlogix Announces Voting Results from the 2020 Meeting of Shareholders and Update on $13 Million Investment by Sheikh Abdulgader Aboud Baeshen
Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual and Special Meeting of Shareholders (the “Meeting”) in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected six (6) Board members...
Dec 22, 2020 07:30 am ET
Resverlogix Announces Apabetalone Treatment Prior to SARS-CoV-2 (COVID-19) Exposure Significantly Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) is pleased to announce recent published findings in the high-impact journal, Proceedings of the National Academy of Sciences (PNAS), that further supports other 2020 publications and...
Nov 20, 2020 06:28 pm ET
Resverlogix Files Notice of Annual and Special Meeting of Shareholders
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the filing on SEDAR (www.sedar.com) of the Notice of Meeting and Management Information Circular (the “Notice”) related to its Annual and Special Meeting of Shareholders...
Nov 20, 2020 06:27 pm ET
Zenith Files Notice of Annual and Special Meeting of Shareholders
Zenith Capital Corp. (“Zenith” or the “Company”) today announces the filing on SEDAR (www.sedar.com) of the Notice of Meeting and Management Information Circular (the “Notice”) related to its Annual and Special Meeting of Shareholders (the...
Nov 12, 2020 08:00 am ET
Resverlogix Announces Publication in High-impact, Peer-reviewed Journal, Clinical Epigenetics
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with...
Nov 02, 2020 07:30 am ET
Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) is pleased to announce today highly significant findings on synergy on improved renal function, as measured by estimated glomerular filtration rate (eGFR), and glucose control, as...
Oct 28, 2020 10:10 am ET
Zenith Confirms Interim Filings on SEDAR
Zenith Capital Corp. (“Zenith” or the “Company”) today announces that, further to its October 9, 2020 press release, it today has filed its interim financial statements and related MD&A for the three months ended July 31, 2020 (the “Interim...
Oct 26, 2020 08:00 am ET
A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that its late-stage clinical candidate, apabetalone, has been prominently featured in a recent article, titled: “Protein-driven mechanism of multiorgan damage in...
Oct 15, 2020 08:00 am ET
Resverlogix Announces Presentations at Leading Scientific Conferences
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today its participation during the following leading scientific conferences: American Society of Nephrology (ASN) Kidney Week Reimagined 2020, 13th Clinical Trials on...
Oct 14, 2020 07:30 am ET
Resverlogix Announces Conversion of US$12 Million Debenture Strengthening Balance Sheet
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that Vision Leader Limited, a wholly-owned subsidiary of ORI Star Fund LP (“ORI”), has delivered a notice of conversion to convert its entire September 2019 debenture and...
Oct 09, 2020 07:56 pm ET
Zenith Provides Update Regarding Extension of its Filing Calendar
Zenith Capital Corp. (“Zenith” or the “Company”) today announces that it has filed its annual financial statements for the year ended April 30, 2020 and related management's discussion and analysis pursuant to National Instrument 51-102...
Oct 06, 2020 07:30 am ET
Resverlogix Announces $13 Million Private Placement
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has entered into a definitive stock purchase agreement for a private placement of 10,560,000 equity units at a price of $1.25 per unit for gross proceeds of $13.2...
Oct 05, 2020 08:00 am ET
Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications
Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the execution of a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) to develop ZEN-3694 for multiple oncology indications. For the...
Oct 02, 2020 06:13 pm ET
Resverlogix Confirms Interim Filings on SEDAR
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that, further to its September 25, 2020 press release, it today has filed its interim financial statements and related MD&A for the three months ended July 31, 2020 (the...
Sep 25, 2020 06:30 pm ET
Resverlogix Provides Update Regarding Extension of its Filing Calendar
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that further to its September 11, 2020 press release, it continues to expect to file its interim financial statements and related MD&A for the three months ended July 31, 2020...
Sep 15, 2020 08:00 am ET
Resverlogix Announces Publication in High-impact Peer-reviewed Journal – Medicinal Research Reviews
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases”, in the peer-reviewed Medicinal...
Sep 11, 2020 08:18 pm ET
Resverlogix Provides Update Regarding Extension of its Filing Calendar
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that it has filed its annual financial statements for the year ended April 30, 2020, related MD&A and annual information form pursuant to National Instrument 51-102...
Sep 08, 2020 08:00 am ET
Resverlogix Announces Participation at the Upcoming Global Chinese Financial Forum (“GCFF”) Virtual Conference 2020 – Investing in Innovation
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces its participation at the GCFF Virtual Conference 2020 - Investing in Innovation (“GCFF Virtual Conference”) on September 10, 2020. Donald McCaffrey, the Company’s President and...
Aug 28, 2020 06:30 pm ET
Resverlogix Provides Update Regarding Extension of its Filing Calendar
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that, further to its July 28, 2020 press release, it continues to rely on blanket exemptions issued by provincial securities commissions due to the COVID-19 outbreak that permit...
Aug 26, 2020 06:00 pm ET
Zenith Announces Extension of its Filing Calendar Based on Continuous Disclosure Exemption
Zenith Capital Corp. (“Zenith” or the “Company”) today announces that it intends to rely on blanket exemptions issued by provincial securities commissions due to the COVID-19 outbreak that permit the Company to extend the filing deadline of certain...
Aug 14, 2020 06:19 pm ET
Resverlogix Announces Private Placement
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today it has closed a private placement of 3,573,333 equity units at a price of $0.75 per unit for gross proceeds of approximately $2.7 million (US$2.0 million). Each unit was...
Aug 04, 2020 08:00 am ET
Resverlogix Announces Publication on Apabetalone in Cardiovascular Therapeutics
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce today the recent publication of an article titled: “Epigenetic modulation by apabetalone counters cytokine driven acute phase response in vitro, in mice and in...
Jul 29, 2020 08:00 am ET
Zenith Epigenetics Advances ZEN-3694 in Multiple Cancer Programs
Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today significant clinical advances of ZEN-3694, the Company’s lead therapeutic compound being developed for epigenetic combination therapies in multiple oncology indications. “Merck,...
Jul 28, 2020 06:00 pm ET
Resverlogix Announces Extension of its Filing Calendar Based on Continuous Disclosure Exemption
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that it intends to rely on blanket exemptions issued by provincial securities commissions due to the COVID-19 outbreak that permit the Company to extend the filing deadline of...
Jul 22, 2020 07:00 am ET
Resverlogix Secures One-Year Extension of Maturity Date of Debenture
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has closed a one-year extension of the maturity date of its debenture. Mr. Donald McCaffrey, President and CEO stated, "We are very pleased that the debenture has...
Jun 22, 2020 07:00 am ET
Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that the U.S. Food & Drug Administration (FDA) has accepted its BETonMACE2 clinical plan as a registration enabling study with positive implications for Resverlogix and its ongoing...
Jun 16, 2020 07:00 am ET
Zenith Announces Corporate Update Conference Call & Webcast on June 18, 2020 and US$5 Million Equity Investment
Zenith Capital Corp. (“Zenith” or the “Company”) today announces it will be hosting a corporate update via conference call and webcast on Thursday, June 18, 2020 at 9:00 am MT / 11:00 am ET. Mr. Donald McCaffrey, President and Chief Executive...
Jun 09, 2020 08:30 am ET
Resverlogix Announces Key BETonMACE Renal Data from Plenary Session Presentation at ERA-EDTA Virtual Congress
Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce key data from its BETonMACE clinical trial in pre-specified stage 3 chronic kidney disease (CKD) patients. This data was presented in a virtual oral plenary session at the 57th...
Jun 05, 2020 06:54 pm ET
Resverlogix Announces Corporate Update Conference Call & Webcast on June 10, 2020 and Upcoming Presentation at the 57th ERA-EDTA Virtual Congress on June 9, 2020
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce the Company will host a Corporate Update Conference Call and Webcast on June 10th, 2020 at 9 am MT/11 am ET. The Company also announces its participation at the...
Jun 01, 2020 08:30 am ET
Resverlogix Plans COVID-19 Clinical Trial Program Launch
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that it is moving forward with a plan to further evaluate apabetalone’s impact on COVID-19 in both a preclinical and clinical setting. A first step will be to...
Mar 31, 2020 08:00 am ET
Resverlogix Announces Participation at the American College of Cardiology Scientific Sessions together with the World Congress of Cardiology Virtual
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today its participation at the American College of Cardiology Scientific Sessions, together with the World Congress of Cardiology (ACC.20/WCC), presenting two virtual posters...
Mar 30, 2020 08:00 am ET
Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical Association
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary...
Mar 24, 2020 08:00 am ET
Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce a March 23, 2020 bioRxiv publication that has shown apabetalone to inhibit specialized proteins – called bromodomain and extraterminal domain (BET) proteins – from...
Mar 23, 2020 07:00 am ET
Resverlogix Invites Collaborations for use of Apabetalone in Trials and Studies to Combat the Spread of COVID-19 Based on New Research
Resverlogix Corp. (“Resverlogix”) (TSX: RVX) announces that it is seeking to collaborate with organizations currently testing therapies for SARS-CoV-2 (the virus responsible for COVID-19) in pre-clinical or clinical models. Apabetalone prevents...
Feb 03, 2020 07:30 am ET
Resverlogix Receives US FDA Breakthrough Therapy Designation for Apabetalone
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) is pleased to announce the U.S. Food & Drug Administration (“FDA”) has granted Breakthrough Therapy Designation for apabetalone in combination with top standard of care, including...
Jan 13, 2020 08:18 am ET
Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) is pleased to announce today additional highly significant findings and clear synergy when apabetalone is combined with anti-diabetic therapies, including dipeptidyl peptidase 4...
Dec 20, 2019 08:30 am ET
Resverlogix Appoints Dicky To to its Board of Directors
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announced that Mr. Dicky To has been appointed to the Company’s Board of Directors. His appointment is effective as of December 19, 2019. Dicky is a partner of ORI Capital and...
Dec 19, 2019 08:58 am ET
Zenith Epigenetics Announces Clinical Advancement of ZEN-3694
Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the significant clinical advances of ZEN-3694, the Company’s lead compound being developed for epigenetic combination therapies in oncology. “I am very pleased to report these...
Dec 11, 2019 08:30 am ET
Resverlogix Announces Change to its Board of Directors
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announced that Dr. Eldon Smith has stepped down from the Board of Directors, effective today. “We would like to thank Eldon for his many years of service and wish him all the...
Dec 05, 2019 06:00 pm ET
Reminder: Resverlogix to Hold Conference Call and Webcast on December 6th, 2019
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) reminds stakeholders that the Company will hold a conference call and webcast on December 6th at 8:30 am ET to supplement the presentation of prespecified BETonMACE cognition results to...
Dec 02, 2019 08:30 am ET
Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that data on apabetalone – and its therapeutic potential for cardiovascular patients experiencing cognitive decline – and the BETonMACE prespecified cognition assessment...
Nov 25, 2019 06:00 pm ET
Resverlogix Announces Warrant Exercise Incentive Program
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) announces a warrant exercise incentive program (“Incentive Program”) designed to encourage the early exercise of 15,593,428 warrants to purchase common shares of the Company. The...
Nov 12, 2019 09:00 am ET
Resverlogix to Hold BETonMACE Conference Call and Webcast on November 18, 2019
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that it has scheduled a conference call and webcast to supplement the presentation of BETonMACE results to be made during the American Heart Association’s (“AHA”) annual...
Oct 31, 2019 07:39 pm ET
Resverlogix Announces Voting Results from the 2019 Annual Meeting of Shareholders
Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual Meeting of Shareholders (the “Meeting”) in Calgary, Alberta. A total of 66,053,596 shares (approximately 31.54% of outstanding common shares) were represented...
Oct 31, 2019 07:36 pm ET
Zenith Announces Voting Results from the 2019 Annual and Special Meeting of Shareholders
Zenith Capital Corp. ("Zenith" or the "Company") announces that, at its annual and special meeting of shareholders held earlier today, Zenith shareholders approved all resolutions outlined in the Notice of Meeting and Management Information...
Sep 30, 2019 07:30 am ET
Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announces that BETonMACE did not meet the primary endpoint – reduction in major adverse cardiovascular events (MACE), defined as cardiovascular death, non-fatal myocardial infarction and...
Sep 27, 2019 09:27 am ET
Resverlogix Announces US$12 Million Debenture Financing and Full Repayment of Loan
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that it has issued a 10% secured convertible debenture in the principal amount of US$12 million (the “Debenture”) to a wholly-owned subsidiary of ORI Star Fund LP (“ORI”...
Sep 26, 2019 07:04 pm ET
Resverlogix to Host BETonMACE Webcast and Conference Call
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that, in connection with BETonMACE topline results, expected to be announced on September 30, 2019, the company plans to hold a webcast and conference call that same...
Sep 26, 2019 09:00 am ET
Toronto Stock Exchange Introduces the TSX30
Canada's premier equities marketplace launches new program to showcase top performing companies, TSX to host market open ceremony September 27
Sep 23, 2019 08:30 am ET
Resverlogix Announces BETonMACE Trial Results Accepted for Presentation at American Heart Association’s Scientific Sessions 2019
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announced today the Late Breaking Science submission, regarding the primary results of the BETonMACE trial, has been accepted by the American Heart Association (“AHA”) for presentation...
Sep 16, 2019 08:30 am ET
Resverlogix Provides Update on BETonMACE Phase 3 Trial
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announced today that, following the completion of final patient safety visits (as reported by the Company on July 8, 2019), the resolution of all outstanding queries is expected within a...
Aug 22, 2019 05:24 pm ET
Resverlogix Announces Annual and Special Meeting of Shareholders
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announced today that its Annual and Special Meeting of Shareholders (the “Meeting”) is to be held Thursday, October 31, 2019 at Mount Royal University, Roderick Mah Centre for Continuous...
Aug 22, 2019 05:24 pm ET
Zenith Announces Annual and Special Meeting of Shareholders
Zenith Capital Corp. (“Zenith”) announced today that its Annual and Special Meeting of Shareholders (the “Meeting”) is to be held Thursday, October 31, 2019 at Mount Royal University, Roderick Mah Centre for Continuous Learning – Ross Glen Hall...
Aug 14, 2019 08:30 am ET
Resverlogix to Present at the European Society of Cardiology’s ESC Congress 2019
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announces today that it will present at ESC Congress 2019, held this year in Paris, France, from August 31 to September 4, 2019, the world’s largest cardiovascular conference. As detailed...
Aug 06, 2019 08:30 am ET
Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694
Zenith Capital Corp. (“Zenith”) announced today that Zenith Epigenetics Ltd. (“Zenith Epigenetics” or the “Company”), a wholly-owned subsidiary of Zenith Capital, has entered into a licensing agreement with Newsoara BioPharma Co., Ltd. (“Newsoara”)...
Aug 02, 2019 12:02 pm ET
Resverlogix Announces Loan Reduction and Extension
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that it has entered into an amending agreement with Third Eye Capital (acting as agent for a syndicate of lenders) to extend the maturity date of the Company’s senior...
Jul 15, 2019 08:30 am ET
Resverlogix Announces Publication on Apabetalone in Clinical Epigenetics
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism” in...
Jul 08, 2019 08:30 am ET
Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) is pleased to announce today that all patients active in BETonMACE, the Company’s event-based, phase 3 registration trial, recently completed their final, follow-up safety visits, marking...
Jun 27, 2019 08:30 am ET
Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a wholly-owned subsidiary of Zenith Capital Corp., announced today that it has dosed the first patient in a Phase 1b/2 clinical trial undertaken in collaboration with Pfizer Inc. (“Pfizer”). The...
Jun 12, 2019 08:30 am ET
Resverlogix Provides Update on BETonMACE Phase 3 Epigenetics Trial
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) is pleased to announce today that all patients active in BETonMACE, the Company’s event-based, phase 3 registration trial, recently completed their last study visits on treatment. Final,...
Jun 10, 2019 08:30 am ET
Resverlogix Announces Participation at Leading, International Scientific Conferences
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announced today its participation at leading, international scientific conferences including: the American Diabetes Association’s (ADA) 79th Scientific Sessions 2019, the 56th European...
Jun 07, 2019 08:48 am ET
IIROC Trade Resumption - RVX.WT.A
TORONTO, June 7, 2019 /CNW/ - Trading resumes in:
Jun 07, 2019 08:31 am ET
Resverlogix Announces Closing of $15 Million Offering
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce today that it has closed its previously announced offering (the “Offering”) of units of the Company (the “Units”). An aggregate of approximately 3.8 million Units...
Jun 07, 2019 08:15 am ET
IIROC Trading Halt - RVX.WT.A
TORONTO, June 7, 2019 /CNW/ - The following issues have been halted by IIROC:
May 15, 2019 08:58 am ET
IIROC Trade Resumption - RVX
TORONTO, May 15, 2019 /CNW/ - Trading resumes in:
May 15, 2019 08:30 am ET
Resverlogix Announces Pricing of Unit Offering
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX)  is pleased to announce today that it has priced its previously announced marketed offering (the “Offering”) of units of the Company (the “Units”) at $4.00 per Unit.  Each Unit consists...
May 15, 2019 08:24 am ET
IIROC Trading Halt - RVX
TORONTO, May 15, 2019 /CNW/ - The following issues have been halted by IIROC:
May 14, 2019 05:36 pm ET
Resverlogix Announces Proposed Offering of Units
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has filed a preliminary short form prospectus with the securities regulatory authorities in  the  provinces of Ontario, Alberta and British Columbia in connection...
May 06, 2019 08:30 am ET
Resverlogix Announces Publication on Apabetalone in High-Impact American Journal of Respiratory and Critical Care Medicine (AJRCCM)
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension” in the...
May 02, 2019 05:12 pm ET
Resverlogix Announces 3-Month Loan Extension
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that it has entered into an amending agreement with Third Eye Capital (acting as agent for a syndicate of lenders) to extend the maturity date of the Company’s senior...
Apr 18, 2019 08:00 am ET
Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) today announces that BETonMACE, the Company’s event-based, phase 3 registration trial has successfully reached 250 projected major adverse cardiac events (MACE), strictly defined as...
Apr 01, 2019 11:00 am ET
Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International Conference on Alzheimer’s & Parkinson’s Diseases
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) today announces that Dr. Jeffrey Cummings, Founding Director of the Cleveland Clinic Lou Ruvo Brain Health Center, Las Vegas, Nevada, gave an oral presentation this past weekend at the...
Apr 01, 2019 08:00 am ET
Resverlogix Announces $15.1 Million of Private Placements
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today it has closed private placements of approximately 4.5 million equity units to Shenzhen Hepalink Pharmaceutical Co. Ltd. (“Hepalink”) and 0.6 million equity units to other...
Mar 27, 2019 12:06 pm ET
Resverlogix Announces Ninth Positive Data Safety Monitoring Board Recommendation for Phase 3 Study of Apabetalone
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) today announces the independent Data and Safety Monitoring Board (DSMB) has completed a ninth planned safety review for the Company's Phase 3, BETonMACE trial for high-risk cardiovascular...
Mar 18, 2019 12:00 pm ET
Resverlogix Proudly Announces Funding for Phase 2 Trial Evaluating Apabetalone in Pulmonary Arterial Hypertension Led by Quebec Heart and Lung Institute – Laval University Researcher
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced the advancement of a $2.9 million project led by academic collaborators at Quebec Heart and Lung Institute, Laval University, to research the clinical potential of its...
Mar 18, 2019 09:00 am ET
Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program
Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a wholly-owned subsidiary of Zenith Capital Corp., announced today that the U.S. Food and Drug Administration (“FDA”) has cleared the Company’s investigational new drug application for ZEN-3694,...
Mar 11, 2019 09:00 am ET
Resverlogix Announces Participation at Prominent Industry and Investor Conferences
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announced today its participation at leading industry and investor conferences during the month of March including, the American College of Cardiology’s (ACC) 68th Annual Scientific...
Jan 31, 2019 06:00 pm ET
Resverlogix Closes $6.6 Million Private Placement with Shenzhen Hepalink
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today it has closed a private placement of approximately 2.2 million equity units to Shenzhen Hepalink Pharmaceutical Co. Ltd. (“Hepalink”) at a price of $3.00 per unit for...
Dec 19, 2018 08:30 am ET
Resverlogix Announces Eighth Positive Data Safety Monitoring Board Recommendation For Phase 3 Study of Apabetalone
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) today announces the independent Data and Safety Monitoring Board (DSMB) has completed an eighth planned safety review for the Company's Phase 3, BETonMACE trial for high-risk...
Nov 28, 2018 08:30 am ET
Resverlogix Announces Publication on Apabetalone in Atherosclerosis Journal
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “Apabetalone downregulates factors and pathways associated with vascular calcification” in Atherosclerosis, the official...
Nov 02, 2018 04:05 pm ET
Resverlogix Closes $13.5 Million Private Placement
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today it has closed a private placement of approximately 4.5 million equity units at a price of $3.00 per unit for gross proceeds of approximately $13.5 million (US$10.3...
Oct 22, 2018 08:30 am ET
Resverlogix Announces Participation at Premier Kidney, Alzheimer’s Disease and Cardiovascular Conferences
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announced today its participation at premier conferences including the American Society of Nephrology (ASN) Kidney Week 2018, Clinical Trials on Alzheimer’s Disease (CTAD) 2018 and the...
Sep 12, 2018 06:30 pm ET
Resverlogix Announces Voting Results from the 2018 Annual and Special Meeting of Shareholders
Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual and Special Meeting of Shareholders (the “Meeting”) in Calgary, Alberta. A total of 126,864,830 shares (approximately 71.50% of outstanding common shares) were...
Sep 04, 2018 08:00 am ET
Resverlogix Presents at Clinical Trials in Alzheimer’s Disease (CTAD) Asia 2018
As a follow up to its July 17, 2018 news release, Resverlogix Corp. (“Resverlogix” or the “Company”) (RVX:TSX) announced today that it has presented at the first Clinical Trials in Alzheimer’s Disease (CTAD) Asia conference in Shanghai, China, this...
Aug 30, 2018 08:00 am ET
Resverlogix Announces $26 Million Private Placement
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today it has closed a private placement of approximately 10.4 million equity units at a price of $2.50 per unit for gross proceeds of approximately $26 million (US$20 million),...
Aug 22, 2018 07:00 am ET
Resverlogix Supports Epigenetics Satellite Symposium and Provides Oral Presentation on Apabetalone at the European Society of Cardiology Congress 2018 in Munich
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) today announced it is supporting a satellite symposium on August 25th, 2018, at the European Society of Cardiology Congress 2018 in Munich, Germany, titled: LDL-c: Done Deal, Next...
Aug 07, 2018 07:00 am ET
Resverlogix Announces Seventh Positive Recommendation From The Data Safety Monitoring Board For Phase 3 Study of Apabetalone
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) today announced  that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase 3 BETonMACE trial in high-risk cardiovascular disease (CVD) patients has completed a...
Jul 31, 2018 05:00 pm ET
Resverlogix Intends to Pursue U.S. Listing
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it intends to pursue a listing of its common shares in the United States. Accordingly, if necessary in order to comply with stock exchange minimum share price...
Jul 17, 2018 07:00 am ET
Resverlogix Announces Upcoming Presentations at Clinical Trials in Alzheimer’s Disease (CTAD) Asia and Alzheimer’s Association International Conference (AAIC)
Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today that it has been awarded two presentations at the Clinical Trials in Alzheimer’s Disease (CTAD) Asia conference in Shanghai, China. Dr. Jeffrey Cummings, Founding Director...
Jul 05, 2018 08:30 am ET
Hemostemix Formalizes World-Class Scientific Advisory Board
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX-V:HEM) is pleased to announce the formalization of its Scientific Advisory Board (“SAB”).   Members of the SAB are all leaders in their fields of expertise, which span biochemistry, molecular...
Jun 14, 2018 03:20 pm ET
Resverlogix Announces FDA Confirmation Regarding Filing Pathway for Apabetalone
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has received confirmation from the U.S. Food and Drug Administration (“FDA”) that BETonMACE, Resverlogix’s on-going Phase 3 study, if successful, is likely to...
Jun 08, 2018 06:39 pm ET
Resverlogix Announces Withdrawal of Public Offering of Units
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has opted not to proceed with the public offering of units of the Company announced on April 17, 2018, based on the Company’s assessment that market conditions are...
Jun 07, 2018 07:00 am ET
Resverlogix Highlights Potential to Develop Apabetalone as a Therapeutic for HIV-1 Eradication Utilizing the “Shock and Kill” Approach
Based on recent findings on apabetalone’s potential role in human immunodeficiency virus (“HIV-1”) eradication, Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is seeking a partnership with an existing stakeholder in the ongoing fight...
May 24, 2018 07:00 am ET
Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that on Friday, May 25, 2018, at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress in Copenhagen, Denmark, the Company is...
May 10, 2018 07:00 am ET
Resverlogix Announces Lifting by TSX of Review
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that, following the previously announced review, the Continued Listing Committee of Toronto Stock Exchange (“TSX”) has determined that the Company satisfies TSX’s...
May 07, 2018 07:00 am ET
Resverlogix Closes US$30 Million Loan
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has closed the previously announced US$30 million senior secured loan (the “Loan”) with Third Eye Capital. The net proceeds of the Loan will be used to fund...
May 01, 2018 07:00 am ET
Resverlogix Advances US$30 Million Loan Closing Documentation
CALGARY, Alberta, May 01, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to update the market today that it is in the final stages of closing documentation in respect of the previously-announced US$30...
Apr 17, 2018 09:00 am ET
Resverlogix Announces Proposed Offering of Units
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Apr 12, 2018 07:00 am ET
Resverlogix Announces TSX Review Update
CALGARY, Alberta, April 12, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today it has received a 30-day extension to no later than May 14, 2018 for the TSX’s review of the Company’s compliance...
Apr 11, 2018 07:00 am ET
Resverlogix Announces US$30 Million Loan Commitment Letter
Resverlogix also Announces the Closing of $3.2 Million in Equity Financing
Mar 28, 2018 07:00 am ET
Resverlogix Announces Two New Publications on Apabetalone in Kidney Disease
CALGARY, Alberta, March 28, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the publication of two new articles on the effect of apabetalone, a novel small molecule BET (bromodomain and extra-terminal) inhibitor, in...
Mar 19, 2018 07:00 am ET
Resverlogix Exceeds Full Enrollment for the Pivotal Phase 3 BETonMACE Clinical Trial
The BETonMACE trial has now surpassed 2,400 enrolled patients and topline data is expected around the end of 2018
Feb 26, 2018 07:00 am ET
Resverlogix Announces Sixth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
A data review by the independent Data Safety Monitoring Board resulted in a recommendation for the BETonMACE trial to continue as planned without any modification
Feb 08, 2018 07:00 am ET
Resverlogix Highlights Key Accomplishments and 2018 Targets
CALGARY, Alberta, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) highlighted today recent key accomplishments and 2018 targets.
Jan 11, 2018 09:33 am ET
Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial
Patient enrollment in the United States is expected to commence this quarter
Jan 08, 2018 08:57 am ET
Resverlogix and Medison Pharma Ltd. Announce Strategic Licensing Agreement
Alliance to focus on regulatory approval, commercialization and marketing of novel apabetalone therapy in Israel
Dec 14, 2017 07:27 pm ET
Resverlogix Announces Filing of Quarterly Financial Statements and Management’s Discussion & Analysis
CALGARY, Alberta, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announced today that it has filed its unaudited interim Consolidated Financial Statements and Management’s Discussion & Analysis for the quarter ended October 31,...
Dec 12, 2017 08:08 pm ET
Resverlogix Announces Voting Results From The 2017 Annual Meeting Of Shareholders
CALGARY, Alberta, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) announced today that, at its annual meeting of shareholders held on December 12, 2017, Resverlogix shareholders approved all resolutions outlined in the Notice...
Dec 12, 2017 07:30 am ET
Nature’s Recent Scientific Reports Publication Describes How Apabetalone May Be a Powerful Agent Against HIV-1
CALGARY, Alberta, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today that a recent Nature Scientific Reports has published a 12 page publication on BET (bromodomain and extra-terminal) inhibitors; RVX-208 (apabetalone) and...
Dec 06, 2017 07:16 pm ET
Resverlogix Repays $68.8 Million Loan
CALGARY, Alberta, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has repaid, in full, its CAD$68.8 million Loan (the “Loan”). Upon repayment of the Loan, the Company has no...
Dec 04, 2017 07:00 am ET
Resverlogix Closes Previously Announced $87 Million Private Placement with Shenzhen Hepalink
CALGARY, Alberta, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has closed its previously announced private placement of 60,416,667 equity units to Shenzhen Hepalink Pharmaceutical Co. Ltd. (“Hepalink”) at...
Nov 02, 2017 08:00 am ET
Resverlogix Announces Participation in Upcoming Conferences
CALGARY, Alberta, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) is pleased to announce the Company’s participation in the following upcoming industry conferences.
Nov 01, 2017 08:00 am ET
Resverlogix Announces Fifth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
A data review by the independent Data Safety Monitoring Board resulted in a recommendation for the BETonMACE trial to continue as planned without any modification
Oct 24, 2017 07:00 am ET
Resverlogix Announces Right of First Refusal Agreement with Hepalink USA Inc.
CALGARY, Alberta, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced that it has entered into a Right of First Refusal Agreement (the “Agreement”) with Hepalink USA Inc. (“Hepalink USA”). Under the Agreement, Hepalink USA was granted a right of first refusal in connection with the licensing of the right to develop, manufacture and commercialize pharmaceutical products containing RVX-208 (apabetalone) in the United States (the “US Licensing Rights”) until April 15, 2019. Hepalink USA paid $8 million (the “Fee”) to Resverlogix in considerat...
Oct 13, 2017 10:42 am ET
IIROC Trade Resumption - RVX
TORONTO, Oct. 13, 2017 /CNW/ - Trading resumes in:
Oct 13, 2017 10:31 am ET
IIROC Trading Halt - RVX
TORONTO, Oct. 13, 2017 /CNW/ - The following issues have been halted by IIROC:
Oct 13, 2017 09:33 am ET
IIROC Trade Resumption - Resverlogix Corp.
Toronto, Ontario--(Newsfile Corp. - October 13, 2017) - Trading resumes in:
Oct 13, 2017 09:22 am ET
IIROC Trade Halt - Resverlogix Corp.
Toronto, Ontario--(Newsfile Corp. - October 13, 2017) - The following issues have been halted by IIROC:
Oct 02, 2017 06:19 pm ET
Resverlogix Announces Annual and Special Meeting of Shareholders
CALGARY, Alberta, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announced today that its Annual and Special Meeting of Shareholders (the “Meeting”) is to be held Tuesday, December 12, 2017 at Mount Royal University, Ross Glenn Hall (Room EC1040), 4825 Mount Royal Gate SW, Calgary, Alberta, commencing at 1:00 pm (MT)....
Sep 13, 2017 07:41 pm ET
Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis
CALGARY, Sept. 13, 2017 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has filed its unaudited interim Consolidated Financial Statements and Management's Discussion & Analysis for the quarter ended July 31, 2017 and related Management's Discussion and Analysis with Canadian securities regulatory authorities.
Sep 13, 2017 07:41 pm ET
Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis
CALGARY, Sept. 13, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has filed its unaudited interim Consolidated Financial Statements and Management's Discussion & Analysis for the quarter ended July 31, 2017 and related Management's Discussion and Analysis with Canadian securities regulatory authorities.
Sep 05, 2017 08:00 am ET
Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
CALGARY, Sept. 5, 2017 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has closed the previously announced extension of the Company's loan. The maturity date of the $68.8 million loan has been extended to December 26, 2017 on the terms and conditions that were announced on August 28, 2017.
Sep 05, 2017 08:00 am ET
Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
CALGARY, Sept. 5, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has closed the previously announced extension of the Company's loan. The maturity date of the $68.8 million loan has been extended to December 26, 2017 on the terms and conditions that were announced on August 28, 2017.
Aug 29, 2017 01:56 pm ET
Successful CANTOS Inflammation Trial Supports Rationale for Resverlogix' Ongoing BETonMACE Trial
CALGARY, Aug. 29, 2017 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that key findings from the recently completed CANTOS trial, which demonstrate that targeting residual inflammatory risk resulted in a reduction in the incidence of Major Adverse Cardiovascular Events ("MACE"), validate the importance of reducing inflammation as a therapeutic strategy for treating Cardiovascular Disease ("CVD").
Aug 29, 2017 01:56 pm ET
Successful CANTOS Inflammation Trial Supports Rationale for Resverlogix' Ongoing BETonMACE Trial
CALGARY, Aug. 29, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that key findings from the recently completed CANTOS trial, which demonstrate that targeting residual inflammatory risk resulted in a reduction in the incidence of Major Adverse Cardiovascular Events ("MACE"), validate the importance of reducing inflammation as a therapeutic strategy for treating Cardiovascular Disease ("CVD").
Aug 28, 2017 08:00 am ET
Resverlogix Announces Extension of Maturity Date of Loan and Expression of Interest Regarding Strategic Transaction
CALGARY, Aug. 28, 2017 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the following update on its corporate activities.
Aug 28, 2017 08:00 am ET
Resverlogix Announces Extension of Maturity Date of Loan and Expression of Interest Regarding Strategic Transaction
CALGARY, Aug. 28, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the following update on its corporate activities.
Jul 25, 2017 07:30 pm ET
Resverlogix Files 2017 Year-End Disclosure Documents and Announces Plans to Host a Symposium at the European Society of Cardiology Congress 2017
CALGARY, July 25, 2017 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it filed its audited Consolidated Financial Statements for the year ended April 30, 2017 and related Management's Discussion and Analysis with Canadian securities regulatory authorities. The Company has also filed its Annual Information Form for the year ended April 30, 2017. Copies of these documents may be obtained online at www.sedar.com, or the Company's website, www.resverlogix.com, or by emailing [email protected] An additional corporate financial update will take place pr
Jul 25, 2017 07:30 pm ET
Resverlogix Files 2017 Year-End Disclosure Documents and Announces Plans to Host a Symposium at the European Society of Cardiology Congress 2017
CALGARY, July 25, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it filed its audited Consolidated Financial Statements for the year ended April 30, 2017 and related Management's Discussion and Analysis with Canadian securities regulatory authorities. The Company has also filed its Annual Information Form for the year ended April 30, 2017. Copies of these documents may be obtained online at www.sedar.com, or the Company's website, www.resverlogix.com, or by emailing [email protected] An additional corporate financial update will take p
Jul 25, 2017 10:10 am ET
IIROC Trade Resumption - RVX
TORONTO, July 25, 2017 /CNW/ - Trading resumes in:
Jul 25, 2017 10:00 am ET
Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial
"BETonMACE Phase 3 Trial with apabetalone to expand to include the United States"
Jul 25, 2017 10:00 am ET
Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial
"BETonMACE Phase 3 Trial with apabetalone to expand to include the United States"
Jul 25, 2017 09:15 am ET
IIROC Trading Halt - RVX
TORONTO, July 25, 2017 /CNW/ - The following issues have been halted by IIROC:
Jul 10, 2017 08:00 am ET
Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial
CALGARY, July 10, 2017 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced  that the first patient has been randomized in Taiwan in the Phase 3 BETonMACE clinical trial with lead drug apabetalone intended for high-risk patients with cardiovascular disease ("CVD") and type 2 diabetes mellitus ("DM").
Jul 10, 2017 08:00 am ET
Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial
CALGARY, July 10, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced  that the first patient has been randomized in Taiwan in the Phase 3 BETonMACE clinical trial with lead drug apabetalone intended for high-risk patients with cardiovascular disease ("CVD") and type 2 diabetes mellitus ("DM").
Jun 29, 2017 08:45 am ET
The Life Sciences Report Examines How With Completion of Offer, Analyst Says This Biotech Stock Could Triple
A Canadian company with its lead drug candidate in a Phase 3 trial recently closed an offering that raised CA$10 million for future research, which has one analyst contemplating the potential.Included in this article is: Resverlogix Corp. (TSX:...
Jun 28, 2017 08:00 am ET
Resverlogix Announces Fourth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
A data review by the independent Data Safety Monitoring Board resulted in a recommendation for the BETonMACE trial to continue as planned without any modification.
Jun 28, 2017 08:00 am ET
Resverlogix Announces Fourth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
A data review by the independent Data Safety Monitoring Board resulted in a recommendation for the BETonMACE trial to continue as planned without any modification.
Jun 21, 2017 10:27 am ET
Resverlogix Comments on TSX Trader Notes
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jun 20, 2017 10:34 am ET
Resverlogix Closes $10 Million of Equity Subscriptions
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATIONIN THE UNITED STATES/
Jun 09, 2017 10:50 am ET
Resverlogix to Raise Up To $10 Million
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jun 08, 2017 05:01 pm ET
Resverlogix Announces Overnight Marketed Equity Offering
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jun 05, 2017 07:55 am ET
Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017
CALGARY, June 5, 2017 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that a recently submitted paper titled: "Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)" was published in the Journal of Cardiovascular Translational Research. The Company also provided details of its upcoming participation in an upcoming industry conference.
Jun 05, 2017 07:55 am ET
Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017
CALGARY, June 5, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that a recently submitted paper titled: "Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)" was published in the Journal of Cardiovascular Translational Research. The Company also provided details of its upcoming participation in an upcoming industry conference.
May 31, 2017 08:00 am ET
Resverlogix To Host Epigenetics Focused Symposium At The ERA-EDTA Congress in Madrid, Spain
The symposium titled: "Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?" at the ERA-EDTA Congress highlights BET-inhibition and apabetalone in addressing the significant unmet medical need in chronic kidney disease and cardiovascular disease.
May 31, 2017 08:00 am ET
Resverlogix To Host Epigenetics Focused Symposium At The ERA-EDTA Congress in Madrid, Spain
The symposium titled: "Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?" at the ERA-EDTA Congress highlights BET-inhibition and apabetalone in addressing the significant unmet medical need in chronic kidney disease and cardiovascular disease.
May 30, 2017 08:00 am ET
Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone
Apabetalone expands in to first orphan disease clinical trial in patients with Fabry disease
May 30, 2017 08:00 am ET
Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone
Apabetalone expands in to first orphan disease clinical trial in patients with Fabry disease
May 23, 2017 08:00 am ET
Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success
Nature Reviews Nephrology and Pfizer Inc. discuss BET bromodomain inhibition and apabetalone as viable drug candidates
May 23, 2017 08:00 am ET
Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success
Nature Reviews Nephrology and Pfizer Inc. discuss BET bromodomain inhibition and apabetalone as viable drug candidates
May 15, 2017 10:35 am ET
May 15, 2017 10:35 am ET
Mar 17, 2017 08:00 am ET
Resverlogix Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone and Provides an Update on Corporate Activities
A data review by the independent Data Safety Monitoring Board resulted in a recommendation for the BETonMACE trial to continue as planned without any modification.
Mar 17, 2017 08:00 am ET
Resverlogix Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone and Provides an Update on Corporate Activities
A data review by the independent Data Safety Monitoring Board resulted in a recommendation for the BETonMACE trial to continue as planned without any modification.
Mar 15, 2017 08:00 am ET
Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office
CALGARY, March 15, 2017 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced the receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent claims covering the use of apabetalone in combination with Rosuvastatin in the United States. Rosuvastatin was exclusively marketed by AstraZeneca under the trade name Crestor® until its patent expired in 2016. The allowed patent is entitled: "Compositions and Therapeutic Methods for Accelerated Plaque Regression," and covers claims for both a single composition as well as separ
Mar 15, 2017 08:00 am ET
Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office
CALGARY, March 15, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced the receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent claims covering the use of apabetalone in combination with Rosuvastatin in the United States. Rosuvastatin was exclusively marketed by AstraZeneca under the trade name Crestor® until its patent expired in 2016. The allowed patent is entitled: "Compositions and Therapeutic Methods for Accelerated Plaque Regression," and covers claims for both a single composition as well a
Feb 13, 2017 07:00 am ET
Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy (FSHD) and Neurodegenerative Eye Disease
Emergence of new potential indications for apabetalone (RVX-208) via third party research
Feb 13, 2017 07:00 am ET
Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy (FSHD) and Neurodegenerative Eye Disease
Emergence of new potential indications for apabetalone (RVX-208) via third party research
Jan 23, 2017 07:00 am ET
Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments
Several Key Proteins That Drive Kidney (Renal) Disease and Dialysis Risk are Downregulated After a Single Dose of Apabetalone
Jan 23, 2017 07:00 am ET
Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments
Several Key Proteins That Drive Kidney (Renal) Disease and Dialysis Risk are Downregulated After a Single Dose of Apabetalone
Jan 05, 2017 05:43 pm ET
Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA
CALGARY, Jan. 5, 2017 /CNW/ - Resverlogix Corp. ("Resverlogix", or the "Company") (TSX:RVX) today announces its participation in the 9th Annual Biotech Showcase Conference during J.P. Morgan week in San Francisco, CA. Mr. Donald J. McCaffrey, President and CEO, will provide a corporate update and overview of recent activities at the conference.
Jan 05, 2017 05:43 pm ET
Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA
CALGARY, Jan. 5, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix", or the "Company") (TSX:RVX) today announces its participation in the 9th Annual Biotech Showcase Conference during J.P. Morgan week in San Francisco, CA. Mr. Donald J. McCaffrey, President and CEO, will provide a corporate update and overview of recent activities at the conference.
Dec 15, 2016 11:24 pm ET
Resverlogix Announces Voting Results From The 2016 Annual And Special Meeting Of Shareholders
CALGARY, Dec. 15, 2016 /CNW/ - Resverlogix Corp. ("Resverlogix", or the "Corporation") (TSX: RVX) today announced that, at its annual and special meeting of shareholders held on December 15, 2016, Resverlogix shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated November 3, 2016 (the "Information Circular"), which is available on SEDAR at www.sedar.com, and on the Resverlogix website at www.resverlogix.com.
Dec 15, 2016 11:24 pm ET
Resverlogix Announces Voting Results From The 2016 Annual And Special Meeting Of Shareholders
CALGARY, Dec. 15, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix", or the "Corporation") (TSX: RVX) today announced that, at its annual and special meeting of shareholders held on December 15, 2016, Resverlogix shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated November 3, 2016 (the "Information Circular"), which is available on SEDAR at www.sedar.com, and on the Resverlogix website at www.resverlogix.com.
Dec 13, 2016 06:28 pm ET
Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis
CALGARY, Dec. 13, 2016 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has filed its unaudited interim Consolidated Financial Statements and Management's Discussion & Analysis for the quarter ended October 31, 2016 and related Management's Discussion and Analysis with Canadian securities regulatory authorities. Copies of these documents may be obtained online at www.sedar.com, or the Company's website, www.resverlogix.com, or by emailing [email protected]
Dec 13, 2016 06:28 pm ET
Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis
CALGARY, Dec. 13, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has filed its unaudited interim Consolidated Financial Statements and Management's Discussion & Analysis for the quarter ended October 31, 2016 and related Management's Discussion and Analysis with Canadian securities regulatory authorities. Copies of these documents may be obtained online at www.sedar.com, or the Company's website, www.resverlogix.com, or by emailing [email protected]
Dec 05, 2016 12:13 pm ET
Resverlogix Announces Second Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)
A data review by the independent Data Safety Monitoring Board resulted in a recommendation for the BETonMACE trial to continue as planned without any modification.
Dec 05, 2016 12:13 pm ET
Resverlogix Announces Second Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)
A data review by the independent Data Safety Monitoring Board resulted in a recommendation for the BETonMACE trial to continue as planned without any modification.
Nov 17, 2016 08:00 am ET
Resverlogix Announces Successful Phase 1 Renal Trial Results: Clears Path for Future Phase 2 Studies
The successful completion of this Phase 1 pharmacokinetic (PK) trial in patients with severe renal impairment clears the path for the Company to further expand its previously announced Renal and Orphan programs